| 138.45 -1.85 (-1.32%) | 07-30 10:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 166.34 | 1-year : | 194.29 |
| Resists | First : | 142.41 | Second : | 166.34 |
| Pivot price | 135.92  |
|||
| Supports | First : | 131.65 | Second : | 125 |
| MAs | MA(5) : | 139.35 |
MA(20) : | 134.7 |
| MA(100) : | 122.78 |
MA(250) : | 129.19 |
|
| MACD | MACD : | 2.5 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 86.7 |
D(3) : | 84.3 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 159.31 | Low : | 108.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ A ] has closed below upper band by 22.8%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 142.19 - 142.88 | 142.88 - 143.56 |
| Low: | 137.15 - 138.03 | 138.03 - 138.88 |
| Close: | 138.69 - 140.08 | 140.08 - 141.44 |
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Wed, 29 Jul 2026
Ningbo Researchers Get Tools to Study PFAS and Potential Health Effects - Stock Titan
Tue, 28 Jul 2026
Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Tue, 28 Jul 2026
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26 - Business Wire
Mon, 27 Jul 2026
Agilent Technologies Inc (A): GF Score of 94 Signals Strong Outp - GuruFocus
Mon, 27 Jul 2026
Agilent Technologies price driven lower by important resistance - Forecast today - 27-07-2026 - Economies.com
Mon, 27 Jul 2026
Precision Trading with Agilent Technologies Inc. (A) Risk Zones - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 282 (M) |
| Shares Float | 281 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 94.2 (%) |
| Shares Short | 7,540 (K) |
| Shares Short P.Month | 5,660 (K) |
| EPS | 4.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.23 |
| Profit Margin | 19.5 % |
| Operating Margin | 23.7 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 21.3 % |
| Qtrly Rev. Growth | 10 % |
| Gross Profit (p.s.) | 13.49 |
| Sales Per Share | 25.59 |
| EBITDA (p.s.) | 7.15 |
| Qtrly Earnings Growth | 60 % |
| Operating Cash Flow | 1,450 (M) |
| Levered Free Cash Flow | 931 (M) |
| PE Ratio | 28.05 |
| PEG Ratio | 1.2 |
| Price to Book value | 5.52 |
| Price to Sales | 5.44 |
| Price to Cash Flow | 27.15 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|